ClinicalTrials.gg

Program

Pan-RAS Molecular Glue ERAS-0015

Also written as “ERAS-0015”, “ERAS-0015 in combination” and “JYP0015”.

Its studies are mostly in Neoplasm Metastasis · Lung Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 2, since May 14, 20253 company-led studies, 3 open or runningNext primary completion: May 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Erasca11 open or runningphase 1since May 14, 2025May 14, 2025May 1, 2028phase 1 · NCT06983743
Guangzhou JOYO Pharma11 open or runningphase 2since Mar 19, 2025Mar 19, 2025none ahead
Tango Therapeutics11 open or runningphase 2since Oct 20, 2026Oct 20, 2026Nov 2031phase 2 · NCT07897734

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2025First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Guangzhou JOYO PharmaGuangzhou JOYO Pharma · NCT06895031 · 210 planned · China
  2. May 14, 2025Erasca’s first study: phase 1 study in Neoplasm MetastasisNew to ErascaErasca · NCT06983743 · 600 planned · United States, Canada, South Korea
  3. Oct 20, 2026Tango Therapeutics’ first study: phase 2 study in Lung NeoplasmsNew to Tango TherapeuticsTango Therapeutics · NCT07897734 · 188 planned

Ahead

  1. May 1, 2028Primary completion: phase 1 study in Neoplasm MetastasisErasca · NCT06983743
  2. Nov 2031Primary completion: phase 2 study in Lung NeoplasmsTango Therapeutics · NCT07897734

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07897734Lung Neoplasms2Not yet recruitingTango TherapeuticsNov 2031188
NCT06983743Neoplasm Metastasis · United States, Canada, South Korea1RecruitingErascaMay 1, 2028600
NCT06895031Carcinoma, Non-Small-Cell Lung · China2RecruitingGuangzhou JOYO PharmaMar 30, 2026210

How it is read

Names in the registry

  • “ERAS-0015”, 2 entries
  • “ERAS-0015 in combination”, 1 entry
  • “JYP0015”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Pan-RAS Molecular Glue ERAS-0015 (Erasca): development program | ClinicalTrials.gg